NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Methods Mol Biol. 2024;2797:299-322. doi: 10.1007/978-1-0716-3822-4_22.
Prior analysis of intact and modified protein forms (proteoforms) of KRAS4B isolated from cell lines and tumor samples by top-down mass spectrometry revealed the presence of novel posttranslational modifications (PTMs) and potential evidence of context-specific KRAS4B modifications. However, low endogenous proteoform signal resulted in ineffective characterization, making it difficult to visualize less abundant PTMs or perform follow-up PTM validation using standard proteomic workflows. The NCI RAS Initiative has developed a model system, whereby KRAS4B bearing an N-terminal FLAG tag can be stably expressed within a panel of cancer cell lines. Herein, we present a method for combining immunoprecipitation with complementary proteomic methods to directly analyze N-terminally FLAG-tagged KRAS4B proteoforms and PTMs. We provide detailed protocols for FLAG-KRAS4B purification, proteoform analysis by targeted top-down LC-MS/MS, and validation of abundant PTMs by bottom-up LC-MS/MS with example results.
先前通过自上而下的质谱分析从细胞系和肿瘤样本中分离出的 KRAS4B 完整和修饰蛋白形式(蛋白形式)的分析表明,存在新的翻译后修饰(PTM),并且可能存在特定于上下文的 KRAS4B 修饰的证据。然而,低内源性蛋白形式信号导致特征分析无效,难以可视化较少丰度的 PTM 或使用标准蛋白质组学工作流程进行后续 PTM 验证。NCI RAS 计划已经开发了一种模型系统,通过该系统,带有 N 端 FLAG 标签的 KRAS4B 可以在一系列癌细胞系中稳定表达。在此,我们提出了一种结合免疫沉淀和互补蛋白质组学方法的方法,以直接分析 N 端 FLAG 标记的 KRAS4B 蛋白形式和 PTM。我们提供了详细的 FLAG-KRAS4B 纯化方案,通过靶向自上而下的 LC-MS/MS 进行蛋白形式分析,以及通过示例结果进行丰富 PTM 的 bottom-up LC-MS/MS 验证。